Showing posts with label research. Show all posts
Showing posts with label research. Show all posts

Thursday, July 21, 2016

SolSurvivors Oregon receives $50,000 to partner with researchers on melanoma study

The SolSurvivors Community Engagement Committee.

Exciting news! The project I've been leading in collaboration with Oregon Health & Science University and SolSurvivors has been selected to receive $50,000 from the Patient-Centered Outcomes Research Institute (PCORI). Funds will be used to develop a research study that reflects the needs and interests of melanoma patients and their families.

The award comes from PCORI’s Pipeline to Proposal program, which enables individuals and groups who are not typically involved in the scientific research process to develop partnerships with researchers and spearhead the design of a patient-centered research proposal. Since 2013, we have been awarded a total of $90,000 to build a Community Engagement Committee and support the OHSU Department of Dermatology on engagement activities related to the Melanoma Community Registry.

Last fall, our project team jointly hosted a Melanoma Community Research Forum, where over 90 participants gathered in Portland and Bend to learn about the latest melanoma research and participate in small-group discussions about their experience with melanoma. Themes identified during the event are being used to shape a collaborative research project, as well as a community event to be held in November 2016.

Want to get involved? Send me a note at katie@prettyinpale.org.

About PCORI 
PCORI is an independent, non-profit organization authorized by Congress in 2010 to fund comparative effectiveness research that will provide patients, their caregivers, and clinicians with the evidence needed to make better-informed health and healthcare decisions. PCORI is committed to seeking input from a broad range of stakeholders to guide its work.

Tuesday, October 20, 2015

A patient’s perspective on a patient-centered conference: Highlights from #PCORI2015 (Part 2)



Patients are changing from research subjects to research partners. -Dr. Harlan Krumholz, PCORI board of governors and faculty member at Yale School of Medicine

Day 2

Dr. Joe Selby, executive director of the Patient-Centered Outcomes Research Institute, opened day 2 the PCORI Annual Meeting by giving an overview of the type of research PCORI funds: patient-centered comparative effectiveness research. CER, he said, compares two or more options about things that matter to patients. According to Dr. Selby, this research should be conducted in "real world" settings and should ideally pay attention to differences in effectiveness for different sub-groups of people (e.g. does a particular treatment work better for women than men).

When PCORI began awarding research contracts just a few years ago, most of the funding they offered fell into four broad categories: (1) assessing prevention, diagnosis, and treatment options; (2) addressing disparities; (3) improving health care systems; and (4) communication and dissemination research. Now, PCORI funding mechanisms are becoming increasingly targeted, addressing specific diseases or other topics that have been identified as high priority. These include programs that focus on asthma, MS, and reducing long-term opioid use, among others. PCORI has also become increasingly interested in funding large studies that better represent the entire population.

The morning's keynote presentation was given by Dr. Victor Montori, an endocrinologist and health services researcher at the Mayo Clinic. Dr. Montori gave a compelling presentation on the importance of involving patients in decision making. What's best for a person, he said, depends on what that person values. Dr. Montori also lamented the curent research funding process, which leaves about 85% of scientific proposals unfunded. To do the type of large studies PCORI aims to fund, he argued, research institutions need to end competition and encourage collaboration instead.

During the following panel, which included a number of stakeholders from various health care organizations, Nancy Brown of the American Heart Association said that if patients really understood how the research process worked, they would be horrified. She also said that people don't want to waste their time thinking about their health--it's only when they become sick that health care becomes the center of everything. In the same panel, former U.S. congressman Tony Coelho spoke about the role patient advocacy organizations play in bringing the patient experience to our legislature. He also noted that we all need to advocate for PCORI so that it doesn't disappear in 2018.

After a series of several plenary presentations, I was eager to break out into smaller group sessions. The two breakout sessions I attended on Day 2 highlighted examples of successful awardees from the Communication and Dissemination Research (CDR) program and the Eugene Washington Engagement Awards. In the CDR panel, shared decision-making tools featured prominently as a means of improving communication between patients and their doctors. Some awardees used focus groups to develop and refine their decision-making tools. Research teams found it was crucial to solicit feedback from providers like doctors and nurses in addition to patients so that these tools could realistically be used in the clinic. In the second breakout session, Engagement Award recipients shared examples of "pre-research" activities they had conducted. Some projects used Engagement funds to conduct a needs assessment in their target population. Other projects used their award to build a curriculum to train people to better understand and conduct patient-centered comparative effectiveness research.

During the final breakout session of day 2, I presented as part of a panel discussion on the Pipeline to Proposals. The Pipeline program provides funding to individuals or groups who would not ordinarily receive research funding from PCORI, and trains us step-by-step, so that--theoretically--in three years we will have built the foundation for a successful, full-scale PCORI award application. (Read more about our project.) I enjoyed participating in this session because it gave me a much-needed opportunity to connect with follow Pipeline awardees, but also because I believe this program is truly emblematic of the type of patient-driven research collaborations PCORI was designed to support.

A recent Time magazine article (that I found in the airport on my way home from the PCORI conference) addresses a patient-centered research question about breast cancer treatment.


Day 3

Day 3 of the meeting featured a keynote presentation by NIH director Dr. Francis Collins. Even though PCORI is technically a nonprofit entity, not a federal agency like the National Institutes of Health, it was impactful to have the head of AHRQ and the head of NIH lend their time to this conference. I think it helps legitimize PCORI as a credible, scientifically rigorous organization, even though the work they fund is quite a bit different.

On day 3, I attended two very different breakout sessions: one on comparative effectiveness research methods and one on how to use your patient story to make a difference in research.

Over the past few years, PCORI has developed comprehensive methodology standards that govern all aspects of the proposal, from how to involve patients in the research process to how to analyze the data collected during a study. The purpose of following these standards is to ensure research findings are valid and can be replicated. Scientific methods are evaluated based on data quality, study design (e.g. randomized controlled trial or observational study), and how the data is interpreted. The PCORI staff member who lead the session emphasized that, while there is no such thing as the perfect study--there will always be trade-offs--it's important to be cognizant of where weaknesses might be so that you can consider how those weaknesses might impact your results.

The last session I participated in was by far the most hands-on. PCORI's engagement staff spoke about storytelling as a "method" of sparking engagement and collaboration. They also shared a tool they created to walk patients through the process of teasing out bits of their patient story that might be relevant to a research question. While the tool was still in draft form, I loved the concept. I also loved to have something tangible I could take home with me after the conference given that so many of the other sessions were very philosophical and not immediately applicable to my daily work.


Finally took the time to do some sightseeing while visiting Washington D.C.


Major themes and takeaways

  • Communicating research results back to the community is essential for building and maintaining trust (bonus points for involving patients and other stakeholders in developing a plan for sharing research results).
  • PCORI funding announcements are becoming increasingly more targeted and aimed at creating large, pragmatic clinical trials that more broadly reflect the "real world."
  • Rigorous research methods and meaningful patient engagement are equally important to PCORI, even though they can sometimes feel at odds with one another. Many applications they reject are dinged, though, because of their lack of the latter.
  • There's no one-size-fits-all model for engagement, but here are some activities that have been successfully used by PCORI awardees to create meaningful engagement: 
    • (1) Including a patient partner as a co-investigator on the project and compensating them financially as such,
    • (2) Include patients, caregivers, and other stakeholders like physicians on project advisory committees, and
    • (3) Address research questions of interest to patients as identified by online surveys, focus groups, or other meetings.
As I mentioned in my first recap post, overall it was a great event. I'm glad I was given the opportunity to attend. I also look forward to seeing further progress towards socializing and truly implementing patient-centered principles in research and clinical practice.

To learn more or view archived videos from the 2015 PCORI Annual Meeting, visit www.pcori.org.

Wednesday, October 14, 2015

A patient’s perspective on a patient-centered conference: Highlights from #PCORI2015 (Part 1)

Elizabeth Stoos and I at the PCORI national meeting. Elizabeth is the coordinator of the Melanoma Community Registry at OHSU and a partner on my PCORI project.

Last week, I was one of about 200 health care consumers (i.e. cancer survivor, caregiver of a person with a chronic condition) to participate in the Patient Centered Outcomes Research Institute’s, or PCORI’s, first national meeting in Washington, D.C. Although some of the work PCORI does is fairly complex, the basic concept is simple:
  1. Fund research that will help answer questions that are important to real people
  2. Involve real people in the doing research to answer these questions
To do this work, PCORI relies heavily on input from a variety of people: patients and their caregivers, of course, but also physicians, nurses, and health insurers, among others.

As someone who was treated for melanoma more than five years ago, I may not be a “patient” in the most traditional sense of the word, but because of my experience and my relationships with so many others who have been touched by the disease, I can help represent the collective voice of all my “mole mates” to the research world. One way I’ve done this has been by reviewing grant proposals; another way has been by partnering with Dr. Sancy Leachman at Oregon Health & Science University to obtain our own patient-centered research award from PCORI. PCORI invited me to attend this conference to share some of our lessons learned during a panel discussion. Of course, this also gave me access to participate in other sessions and network with other PCORI funding recipients.

In the spirit of helping create a two-way conversation between researchers and the general public, I’ve attempted to summarize some of the highlights from the conference below. PCORI has made some great progess since its inception in 2010, but I think we still have a long way to go to and lots to learn from one another before patients and their families become true partners in the health care decision-making and research process. I’m very thankful that I was given the opportunity to participate in this conference, and look forward to seeing the progress we all make in the coming years.


Day 1: Change is Hard: Challenges and Opportunities in Turning New Evidence into Clinical Practice
“Everything about PCORI is having the right people involved.” –Dr. Eugene Washington 
The first day of the conference was an optional, 5-hour session that was hosted by PCORI in conjunction with AHRQ (another health care research funder) and AcademyHealth. The session included large-group presentations by several of the major players who helped get PCORI off the ground, including AHRQ director Dr. Richard Kronick, PCORI executive director Dr. Joe Selby, and former PCORI board chair Dr. Eugene Washington.

Day 1’s panel discussions were all about dissemination: how do you take a topic that’s already been studied and turn the results of that study into practice? For example, if a team of the nation’s top researchers did a study on skin cancer, and found that eating 10 gummy bears per day prevented skin cancer in adults under 30 years of age, we assume we’d all be stocking up on Haribo. But in the complex world that is our health care system, implementing evidence into practice can take years, sometimes even decades. As the session’s title suggests, implementing research findings into real life practice is hard.

Dr. Mark McClellan, an experienced health care strategist and advisor, spoke about things that might help dissemination of research findings, such as reforming Medicare payment models. He also acknowledged that often times we’re working up against culture change, which inevitably takes time. Bottom line? Although it can be slow-moving, working directly with patients can have a huge impact on effectiveness of dissemination.

Chip Heath, author of Made to Stick, inspires conference attendees to be agents of change.

Panelists during Tuesday’s session agreed that just because something is published in a prestigious medical journal, doesn’t mean it will lead to change in practice. Systematic reviews and clinical practice guidelines can be helpful, particularly for busy clinicians who don’t have time to read 50+ journal articles per day, while others argued that physician assistants and nurses should be able to play a larger role in implementing findings into every day practice. The second panel brought up a few more suggestions: write materials at a reading level that people can actually understand (easier said than done), create materials that are tailored to the population they are targeting (also not as intuitive as you’d expect), encourage clinicians to become more comfortable admitting uncertainty to patients, as well as empowering patients to challenge the system and ask questions (e.g. Do I really need this very expensive MRI?)

One of the panelists, Tara Montgomery from Consumer Reports, challenged us to think about diagnostic tests and medical treatments the way that we buy things like cars and new electronics. She also emphasized that humanizing data and turning it into a story can make it more compelling to the consumer. Some of this responsibility, the panelists said, falls to journalists who can and should be reading the original journal articles.

The afternoon concluded with a totally different type of presentation by bestselling author and Stanford business school professor Chip Heath. After hours of interesting but relatively dry, academic panels, Chip came up on stage and delivered a TED-style talk on how all of us in the room are agents for change. He explained that we all have a “rider” and an “elephant”—one of which is rational and the other more instinctual. Change, he said, happens when we align the elephant and the rider. He explained this using a series of funny anecdotes and examples such as the old vs. new food pyramid and Amazon.com vs. Borders bookstore. His talk, which was viscerally different from any of the preceding talks that day, sent a message that perhaps the medical research community needs to “think outside the box” when it comes to disseminating and implementing evidence-based research.

Overall, it was an intellectually stimulating—albeit long—afternoon, but I left the session feeling a bit powerless and overwhelmed. How can I help bring about change if this group of highly educated, experienced professionals hasn’t quite figured it out yet? Every time I participate in a PCORI review meeting or training, I feel both welcomed by fellow participants, but also a bit intimidated given my lack of post-graduate credentials. Despite being a conference about the importance of consumer engagement, this session still felt very "academic." I hope that in the future, PCORI meetings will become increasing accessible to lay audiences, so that we can more widely start to do the paradigm-shifting work it was created to accomplish.

Change is tough indeed.

Stay tuned for more on Day 2 and Day 3!

Tuesday, March 31, 2015

Getting survivors involved in the design of melanoma research: Our PCORI project advances to Tier 2

Great news to share! The project I've been working on in collaboration with Oregon Health & Science University and SolSurvivors has been selected to advance to Tier 2 of PCORI's Pipeline to Proposals Program. Tier 2 awards provide up to $25,000 to help recipients strengthen community partnerships, develop research capacity, and hone a comparative effectiveness question that could become the basis of a large-scale research project.

Pipeline to Proposal Awards enable individuals and groups that are not typically involved in research (like me!) to develop the means to produce community-led funding proposals focused on patient-centered comparative effectiveness research. In 2014, I was part of the inaugural Tier 1 cohort of this program.

Our project, "Developing Infrastructure for Patient-Centered Melanoma Research," aims to involve patients and other critical stakeholders in the development of strategies for preventing and detecting melanoma at an earlier stage, thereby decreasing death rates. When melanomas are detected early, patients have a 98% five year survival rate, but if the cancer has spead to the lymph nodes and other parts of the body, survival rates drop to a mere 16%*. Because of its origins in the skin—where doctors and patients can see it—melanoma should be one of the most easily recognized and detectable of all cancers. Unfortunately, barriers still exist to early detection of melanoma. During Tier 1, we learned that many patients don’t know what to look for when conducting a skin self-exam. Other barriers to early detection and treatment may include a lack of knowledge that melanoma can be life-threatening, poor/no insurance coverage, lack of transportation/distance to a provider, and treatment by a doctor that lacked expertise in melanoma.

During Tier 1, we began building an “army” of volunteers to attack melanoma prevention from new angles and perspectives. Our greatest accomplishment during the nine-month award period was to support the launch of the Melanoma Community Registry at Oregon Health & Science University. As of January 2015, the Melanoma Community Registry had 2,374 patients, 446 family members of patients, and 146 friends of patients signed up. As director of the project, I contributed by participating in brainstorming meetings, drafting text for recruitment materials, reviewing informed consent language, appearing in TV and newspaper articles promoting the registry, promoting the registry at community events such as the Portland Melanoma Walk, as well as cost-sharing IT development.

In this next phase, we plan to build upon the progress we made in Tier 1, with the ultimate goal of working toward a large-scale research study in collaboration with researchers at OHSU. Specifically, we plan to use surveys and focus groups to identify issues that are the most crucial to melanoma patients and those who care for them. We are also continuing to develop our network and would love to meet others with an interest in contributing to this effort. Want to get involved? Send me a note at info@solsurvivorsusa.org.

View this video to learn more:


PCORI is an independent, non-profit organization authorized by Congress in 2010 to fund comparative effectiveness research that will provide patients, their caregivers, and clinicians with the evidence needed to make better-informed health and healthcare decisions. PCORI is committed to seeking input from a broad range of stakeholders to guide its work.

*National Cancer Institute SEER

Thursday, April 4, 2013

What it means to be a "patient stakeholder"

Greetings from Baltimore, Maryland! I just finished a full day of reviewing grants as a patient stakeholder for the Patient Centered Outcomes Research Institute--aka PCORI. PCORI funds biomedical research, much like the National Institutes of Health, but as its name implies, the research it funds is uniquely "patient centered." What does that mean? Proposals are critiqued not just on their scientific merit but also on their involvement of patients in the research process and their likelihood of solving problems patients identify as most important. Each grant submitted to PCORI is reviewed by both scientists and at least one patient, which is why I had the opportunity to participate in a scientific review process that is typically limited to MDs and PhDs.

The whole process has been fascinating to me. I do have quite extensive experience working with scientists and reading grant proposals--when I'm not blogging, I manage the Research Funding & Development Services program at Oregon Health & Science University. That said, I'm not a scientist. I may help scientists find grants to apply for and advise on writing, but I've never had the opportunity to review a grant for a public or private entity before. In summary, the experience was incredibly rewarding and informative. I encourage anyone who is interested to apply to be a patient or stakeholder reviewer. It's a pretty hefty time commitment, but I know a few fellow health advocates who I think would make tremendous contributions as a reviewer. Feel free to email me if you're considering applying--I'd be happy to answer any questions you have.

Thursday, July 19, 2012

Melanoma and particle physics

Human melanoma cells.
Image: Paul J.Smith & Rachel Errington.
Even the indoor tanning industry admits that UV light causes the most common forms of skin cancer, basal and squamous cell carcinoma. They claim, however, that there is insufficient scientific evidence to prove that UV radiation causes melanoma, a much more rare but lethal form of skin cancer. In a way, they're right. Forgive my far-fetched analogy here, but pinning down the exact molecular mechanism that causes melanoma has been kind of like the physicists at MIT hunting down the Higg's boson. We can see all this evidence suggesting that it exists, but we don't have the technological capacity to prove it. Now that we found the Higg's boson, surely it isn't too much to ask that we determine once and for all that yes, UV radiation causes melanoma? After all, in epidemiological studies, severe sunburns and tanning bed use significantly increase a person's risk for developing the disease. We just need that final bit of information that explains why.

A group of scientists from M.D. Anderson Cancer Center, Dana-Farber Cancer Institute, and the Broad Institute are getting closer. A new paper published this week in Cell identifies six new "melanoma genes," three of which are described by one of the paper's author's as, "The first 'smoking gun' genomic evidence directly linking damage from UV light to melanoma."

This line of research may also guide scientists toward more effective treatments for advanced-stage melanoma. I guess it's not quite as monumental as the discovery of the "God particle," but I'll take what I can get.

Wednesday, June 13, 2012

Spray tans might be bad for you now, too

Woman getting a spray tan.
My mom has been asking me about this for years--but there have literally been no new studies since the 1970s on the safety of DHA (dihydroxyacetone), the active ingredient in most sunless tanning products.

Earlier this week, ABC News did an investigative report that I absolutely frickin' loved! This may come as a surprise to some--I do occasionally use a DHA-based moisturizer before running around in a bikini--but I'm glad that someones finally digging a little deeper and trying to learn more about how DHA interacts with human cells. The report also bashes on the tanning bed industry, which as you know, is one of my favorite pastimes.

In summary: The scientists ABC quoted were heavily concerned by DHA being applied as a spray rather than a lotion. For those of you who have never gotten a Mystic, or spray, tan, they basically shut you in a box and mist you with a really stinky spray for about a minute. It doesn't take very long, but it's not uncommon to feel like you're gagging or choking on the spray. (To me, it seems like that's how you'd feel if you were an ant getting bug bombed.)

While topical application of DHA was approved by the FDA back when my mom was a teenager, according to ABC News:
"The FDA told ABC News it never could have envisioned the chemical's use in spray tan back in the 1970s, and says 'DHA should not be inhaled or ingested"' today. It tells consumers on its website, 'The use of DHA in 'tanning' booths as an all-over spray has not been approved by the FDA, since safety data to support this use has not been submitted to the agency for review and evaluation.'"
So basically, by bombarding our lungs and eyes with this chemical version of DHA, we could be putting ourselves at risk for developing cell abnormalities (a.k.a. cancer). Of course, topical application of sunless tanning products gets attacked, too. New research insights indicate that DHA may penetrate more deeply than we once thought, which means more research needs to be done to determine the costs and benefits of spray tans versus the real thing.

Now, onto my favorite part. I love it when the media does undercover investigations of tanning salons because the results are always the same: mass noncompliance with basic, federal safety recommendations. For example, even though spray tanners are supposed to cover their eyes while they're in the booth, nine out of 12 salons in the report did not have protective eye wear available. Same deal with nose and mouth guards. Apparently, many tanning salon owners are also told that DHA is so healthy, you could drink it! Yum. Mind you, these are the same folks who told me, a melanoma survivor, that UV tanning won't cause cancer.

Essentially, this report affirms several things I've been preaching over the past few months:

1. Stay the heck away from tanning salons. Even if you're not UV tanning, you're still supporting a $5 billion industry that's more concerned with making a profit than it is with your health. Plus, tanning salon operators are trained to sell. While spray tanning before a vacation two years ago, the guy at the front desk tried to sell me a "tanning cocktail" package, which means you do 10 minutes in a UV bed before you go in for your spray tan. Perhaps he just couldn't read English because it explicitly said on my client information card: History of skin cancer.

2. Love your natural skin color! This is a hard one, I know, but if think of how much safer we'd be if we shunned tanning beds of all types--UV and UV-free. Funny story: At a fundraiser earlier this spring, I was having a conversation with a woman about my experience with melanoma. I gave her the rundown about how I used to use tanning beds, but now I've become diligent about sun protection. Her reaction? "Well, at least you can still spray tan." Yes, of course I can still spray tan, but I think she missed the point.

3. Think of sunless tanners as a “nicotine patch” for tanning beds. Despite everything it says in the ABC News report—that DHA has some potential side effects—UV radiation has proven risks. If you’ve got a wedding coming up, opt for an  airbrush tanning session instead of using a UV bed twice a week for the next eight weeks. If the thought of going to the beach without a tan gives you nightmares, use a little Jergens Natural Glow. Just don’t skimp on the SPF, and don’t become one of those people whose palms become perma-orange from self-tanning cream.